MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,
A new instrument to measure chronic kidney disease (CKD) - and transplant-related knowledge in patients with moderate to severe chronic kidney disease.